Entertainment / Los Angeles — Clayface opens at No. 1 with an estimated $24 million domestic weekend from 3,458 theatres, a number whose meaning depends entirely on its unusually small $44 million budget. All weekend figures are Sunday estimates.
The Clayface box office opening weekend now has its headline number — an estimated one. Sunday estimates put the film at No. 1 with an estimated $24 million domestic opening from 3,458 theatres, built on an estimated $10.4 million Friday (including previews) and $3.5 million in Thursday previews. Warner Bros. and DC Studios began preview shows from 2 p.m. on Thursday ahead of the film's wide release on Friday, October 23, in more than 3,400 North American theatres, according to trade coverage by Deadline and Variety on October 23 and 24. On its own, an estimated $24 million sounds modest for a comic-book film. Against this film's cost, it may be something else entirely.
Clayface cost $44 million in net production spending. That figure is the centre of the story, and everything else in this article hangs off it. The film is an R-rated body-horror picture running 108 minutes, directed by James Watkins, from a screenplay by Mike Flanagan with Hossein Amini. Tom Rhys Harries stars as Matt Hagen, the actor who becomes Clayface, alongside Naomi Ackie. It is a DC film built like a horror film, priced like a horror film, and — if the preview number holds through the weekend — potentially capable of earning like one too.
What $3.5 million in previews usually means
Preview grosses are not opening weekends. Thursday previews capture the most motivated audience: fans who bought early and horror viewers who like opening-night crowds. Some films are front-loaded and fade; others, especially horror titles with strong word of mouth, hold through Saturday and leg out for weeks.
The comparisons supplied by the trade coverage make the range concrete. Kraven the Hunter took $2 million in previews and opened to $11 million. Birds of Prey took $4 million in previews and opened to $33 million. Blumhouse's Other Mommy took $3.6 million in previews and opened to $27.8 million. Clayface, at $3.5 million, sits almost exactly on Other Mommy's preview number and just below Birds of Prey, and well above Kraven. The spread between those outcomes — $11 million at one end, $33 million at the other — is a warning against false precision, but it also shows why forecasters are not treating $3.5 million as a failure signal.
Reviews and audience scores explain part of the optimism. Clayface stands at 76 percent Certified Fresh with critics on Rotten Tomatoes — critics in the mid-70s — and 94 percent with audiences, with audience scores around 93-95 percent and 4.5 stars on PostTrak. Audiences also gave it a rare A- CinemaScore, a grade horror releases seldom earn. For an R-rated horror film drawn from a Batman villain most general viewers know, if at all, as a shape-shifting lump of clay from animation and comics, those scores are the asset Warner Bros. most needs this weekend. Horror sells on a simple promise passed between friends: it actually delivers. A 94 percent audience score is that promise, quantified.
How the forecasts did
How the forecasts did: heading into the weekend, the projections formed an unusually wide spread. Warner Bros.' own studio projection was $25 million to $30 million domestically, plus $20 million to $25 million internationally. Deadline projected $20 million to $25 million domestically. Boxoffice Pro projected $25 million to $30 million. Box Office Theory, at the cautious end, projected $15 million to $23 million. The estimated $24 million opening lands inside Deadline's range and just below the studio's own — the wide spread resolved, as it usually is, somewhere in its middle. All of these figures are estimates and projections, not final grosses.
There is, however, a calculation that does not depend on picking a forecaster. A film that cost $44 million net does not need to behave like a tentpole. The traditional rule of thumb — rough and contested, but useful — is that a film needs around two to two-and-a-half times its production budget in worldwide grosses to cover marketing and exhibitor splits and reach profitability. For Clayface, that points to a worldwide target somewhere around $90 million to $110 million, not the $400 million-plus territory a $170 million superhero film must enter before anyone relaxes. The preview number should be judged against that target, not against the opening weekends of films that cost four times as much.
The Supergirl comparison shows the other risk equation
The summer's Supergirl supplies the clearest contrast, and it is not a flattering one for the old model. That film cost a reported $170 million, took $7.8 million in previews across Wednesday fan events and Thursday shows, opened to roughly $37 million to $38 million domestically, and finished at about $126.5 million worldwide — a disappointment, in the trade's own assessment, despite opening numbers far larger than anything Clayface is projected to reach.
Put the two films side by side and the arithmetic is stark. Supergirl's previews were a little more than double Clayface's, but its production cost was nearly four times as high. Supergirl's entire worldwide gross, $126.5 million, would represent a strong success for Clayface; for Supergirl it fell well short of what a $170 million production needed. This is the analysis core of the Clayface bet: DC Studios has not lowered its ambitions so much as changed the size of the wager. A miss at $44 million is a bad quarter. A miss at $170 million is a strategy meeting.
Supporters of the approach argue this is how a studio rebuilds a brand after expensive disappointments — smaller films, distinctive genres, directors with a point of view, and villains or minor characters who would never justify a tentpole budget. Critics answer, also fairly, that horror economics have limits: R ratings cap the teenage audience, body horror narrows it further, and a character without Batman on the poster cannot rely on the most valuable name in DC's catalogue. Both arguments are visible in the same forecast spread. The bulls priced the reviews and the budget; the bears priced the rating and the obscurity.
A crowded weekend, led by a documentary phenomenon
Clayface is not opening into an empty field. Its sharpest competition comes from an unlikely source: A24's Elizabeth Holmes documentary You Can See Everything, from Nathan Fielder and Lance Oppenheim, which expanded from 855 theatres to 2,655 this weekend and holds No. 2 with an estimated $19.5 million in its second weekend, after opening to $15.6 million — the best launch in under 1,000 theatres since Borat in 2006. The documentary added $2.2 million on Thursday, taking its cumulative total to $25.6 million, and it was the number one film in North America on Monday, Wednesday and Thursday.
The smaller openers underline how stratified the market has become. Wicker took $620,000 in previews from 1,471 theatres. Laika's Wildwood took about $1 million in previews. Klara and the Sun took just $85,000 in previews after Sony cut its rollout from roughly 1,900 screens to about 800. Each of those numbers tells the same story from a different seat: opening weekends are now won or lost before Friday, in decisions about theatre counts, preview strategies and which audiences a studio genuinely believes it can reach.
Further down the chart, Street Fighter falls to fifth in its second weekend, with an estimated $8.4 million frame and a cumulative total of about $46.7 million (all estimates).
Why this matters
This matters because Clayface is a test of whether the superhero genre can survive its own economics by shrinking. For a decade, the industry's default answer to a comic-book property was scale — bigger budgets, bigger characters, bigger opening weekends — and the failures of that model have been measured in nine figures. A $44 million R-rated horror film about a supporting Batman villain is the opposite instinct, and its result will be cited in greenlight meetings far beyond DC.
There is a creative argument inside the financial one. Flanagan's involvement signals a film sold on tone rather than spectacle, and Watkins directs horror as a craft of dread and practical effect rather than digital scale. If that package, at that price, returns a profit, the lesson travels: studios can hand distinctive filmmakers minor characters and let genre do the work that marketing budgets used to do. If it fails despite strong reviews, the lesson travels just as fast in the other direction — that audiences will only leave home for comic-book films that feel like events, whatever they cost.
The wider industry context makes the stakes plain. Original and mid-budget films have struggled for screens all year, as our wider entertainment and technology coverage has tracked in stories ranging from studio strategy to new distribution ventures such as the Daytona agent cloud financing. Clayface is not an original film, but its budget belongs to that endangered middle. Its success would be evidence that the middle can still work when a recognisable brand is attached at a survivable price.
What happens next
The next evidence arrives in stages. Monday's actuals will confirm or trim the estimated $24 million opening, and the second weekend's hold will test the A- CinemaScore and the PostTrak score — whether Thursday's fans were the whole audience or its leading edge. The worldwide opening remains a $45-55 million projection, and the international opening — projected at $20 million to $25 million — will decide how much of the $44 million cost the first weekend retires.
For now, the fairest summary is the one the numbers support. A DC film opened at No. 1 with an estimated $24 million — built on $3.5 million in previews, less than half of Supergirl's preview haul, on roughly a quarter of Supergirl's budget, with better audience scores than most horror releases manage; how far word of mouth carries it from here is the remaining question. In a genre that has spent years confusing size with safety, that is precisely what makes this weekend worth watching. Its result will also sit alongside the weekend's very different contest in Rotterdam, covered in our report on Skye Blakely's apparatus finals — two industries, on the same weekend, testing whether smaller and sharper can beat bigger.